ADVFN US – Market Content Editor
-
AppLovin Shares Fall 3.5% as Edgewater Flags Slower Market Share Expansion
AppLovin (NASDAQ:APP) shares fell 3.5% after Edgewater Research analyst Joe Wittine said recent channel checks indicated that growth in the mobile advertising company’s market share metrics had slowed. Wittine forecast AppLovin’s fourth-quarter revenue growth at between 8% and 9% sequentially, below expectations he said had previously been reflected on Wall Street. According to the analyst,…
-
McDonald’s Sets 2030 Margin and Market Share Targets Under New Growth Strategy
McDonald’s Corporation (NYSE:MCD) has outlined a new long-term growth strategy, McDonald’s > NEXT, setting financial and operating targets through 2030 covering margins, restaurant efficiency, market share and systemwide sales. The company presented the strategy at an investor day at its Chicago headquarters on September 23, 2026. McDonald’s is targeting an operating margin in the low-to-mid…
-
Meta Expected to Unveil Camera-Free Smart Glasses at Connect
Meta Platforms (NASDAQ:META) is expected to introduce new smart glasses at its annual Connect conference on Wednesday, including models without cameras, as privacy issues surrounding wearable AI devices receive increased attention. According to The Information, Meta is expected to unveil two camera-free styles, known as Clubmaster and Burbank. The company has established a presence in…
-
General Mills Q1 Earnings Beat Estimates as Revenue Reaches $4.4 Billion
General Mills Inc. (NYSE:GIS) reported first-quarter adjusted earnings and revenue above analyst expectations while reaffirming its fiscal 2027 outlook. Adjusted earnings per diluted share were $0.75, compared with the consensus estimate of $0.72. Revenue was $4.4 billion, above expectations of $4.34 billion but down from $4.5 billion in the same period a year earlier. Net…
-
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus. Its primary endpoint measured the percentage change from baseline in the Cutaneous…
-
Beneficient Seeks Resolution to Eliminate About $130 Million of Disputed Debt Linked to Former CEO
Beneficient (NASDAQ:BENF) said it is seeking an agreement with former Chief Executive Officer Brad Heppner that would eliminate approximately $130 million of disputed debt and restructure his remaining equity and contractual interests in the company. Heppner was convicted on May 7, 2026, of federal charges including securities fraud and wire fraud. According to Beneficient, evidence…
-
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint
Immunovant (NASDAQ:IMVT) shares fell 6% on Monday after the company reported that a proof-of-concept study evaluating IMVT-1402 in cutaneous lupus erythematosus did not meet its primary endpoint. The trial did not achieve statistical significance on its primary endpoint, which measured the percentage change from baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index…
-
Best Buy and Amazon Expand Fire TV Partnership Into Connected TV Advertising
Best Buy (NYSE:BBY) and Amazon (NASDAQ:AMZN) have expanded their multiyear Fire TV partnership to include connected television advertising, extending an existing agreement covering Best Buy’s Insignia TVs. Under the agreement, Fire TV will remain the exclusive software experience across all Insignia televisions produced by Best Buy, with models ranging from 24 to 85 inches. The…
-
Psyence BioMed Agrees Up to $5 Million PsyLabs Investment and Forms Texas Ibogaine Unit
Psyence Biomedical Ltd. (NASDAQ:PBM) has agreed to invest up to $5 million in Psyence Labs Ltd. and enter into a reciprocal share exchange with the company valued at approximately $9 million on each side. Psyence BioMed has irrevocably committed to invest $2.4 million in PsyLabs through the acquisition of 936 ordinary shares at $2,564 per…
-
CGI and D-Wave Quantum Partner on Enterprise Quantum Computing Applications
CGI (NYSE:GIB) and D-Wave Quantum Inc. (NYSE:QBTS) have entered into a strategic partnership focused on developing enterprise applications for quantum computing across sectors including logistics, transportation and retail. The agreement expands on more than a year of collaboration between the companies, according to a joint announcement. Under the partnership, CGI will incorporate D-Wave’s quantum computing…